AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36816342 — intervention group
Group type: EXPERIMENTAL
Intervention: Vixarelimab 360 mg weekly (720 mg loading dose)
Number of subjects: 40
Study 36816342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 36816574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP goals of 110-130 mmHg)
Number of subjects: 6501
Study 36816574 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SBP goals of 130-150 mmHg)
Number of subjects: 6501
Study 36816939 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-course chemoradiotherapy combined with concurrent tislelizumab (50 Gy/25 f, 2 Gy/f, 5 days/week; capecitabine 1000 mg/m2 bid, day 1-14 for three 21-day cycles; tislelizumab 200 mg, day 8 for three 21-day cycles)
Number of subjects: 26
Study 36816939 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-course chemoradiotherapy combined with concurrent tislelizumab
Number of subjects: 26
Study 36817467 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum administered into lymph nodes
Number of subjects: 0
Study 36817467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36817467 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum injections
Number of subjects: 0
Study 36817610 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM)
Number of subjects: 39
Study 36817610 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician outreach
Number of subjects: 39
Study 36817610 — intervention group
Group type: EXPERIMENTAL
Intervention: RPM
Number of subjects: 39
Study 36817762 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT) intervention twice a day plus standard non-pharmacological prevention measures for 5 days after surgery
Number of subjects: 160
Study 36817762 — intervention group
Group type: COMPARATOR
Intervention: Standard non-pharmacological prevention measures
Number of subjects: 160
Study 36817782 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided treatment (PCT)
Number of subjects: 921
Study 36817782 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard antibiotic treatment)
Number of subjects: 921
Study 36818155 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely prescribed and monitored long-term mHealth maintenance exercise programme
Number of subjects: 30
Study 36818155 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 36818468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) infusion using a 15-minute rate escalation protocol
Number of subjects: 123
Study 36818595 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of mRNA vaccine
Number of subjects: 2486
Study 36818595 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of mRNA vaccine
Number of subjects: 2486
Study 36818595 — intervention group
Group type: COMPARATOR
Intervention: Black patients
Number of subjects: 2486
Study 36818595 — intervention group
Group type: COMPARATOR
Intervention: Hispanic patients
Number of subjects: 2486
Study 36818659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learning intervention
Number of subjects: 15
Study 36818659 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15
Study 36818735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal balance restoration and assessment
Number of subjects: 176
Study 36818735 — intervention group
Group type: EXPERIMENTAL
Intervention: Different surgical technical options
Number of subjects: 176
Study 36819512 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium OSF (oral soluble film)
Number of subjects: 60
Study 36819512 — intervention group
Group type: COMPARATOR
Intervention: Montelukast sodium CT (chewable tablet)
Number of subjects: 60
Study 36819512 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium OSF without water
Number of subjects: 60
Study 36819512 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium OSF with water
Number of subjects: 60
Study 36819512 — intervention group
Group type: COMPARATOR
Intervention: Montelukast sodium CT with water
Number of subjects: 60
Study 36819685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement + placebo (SU-PL)
Number of subjects: 31
Study 36819685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement + probiotics (SU-PR)
Number of subjects: 31
Study 36819685 — intervention group
Group type: COMPARATOR
Intervention: Control (individualized diet)
Number of subjects: 31
Study 36819683 — intervention group
Group type: EXPERIMENTAL
Intervention: Roasted barley flakes
Number of subjects: 32
Study 36819683 — intervention group
Group type: EXPERIMENTAL
Intervention: Roasted oat flakes
Number of subjects: 32
Study 36819683 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional barley flakes
Number of subjects: 32
Study 36819683 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional oat flakes
Number of subjects: 32
Study 36819683 — intervention group
Group type: COMPARATOR
Intervention: White toast bread (control)
Number of subjects: 32
Study 36820098 — intervention group
Group type: EXPERIMENTAL
Intervention: BGB-DXP593 5 mg/kg
Number of subjects: 0
Study 36820098 — intervention group
Group type: EXPERIMENTAL
Intervention: BGB-DXP593 15 mg/kg
Number of subjects: 0
Study 36820098 — intervention group
Group type: EXPERIMENTAL
Intervention: BGB-DXP593 30 mg/kg
Number of subjects: 0
Study 36820098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36820100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (systolic target 130-140 mm Hg within 1 h; maintained for 72 h)
Number of subjects: 2196
Study 36820100 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure management (systolic target <180 mm Hg)
Number of subjects: 2196
Study 36820878 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet noninvasive ventilation
Number of subjects: 320
Study 36820878 — intervention group
Group type: COMPARATOR
Intervention: Usual respiratory support
Number of subjects: 320
Study 36820931 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin prophylaxis
Number of subjects: 472
Study 36820931 — intervention group
Group type: COMPARATOR
Intervention: No norfloxacin prophylaxis (Control)
Number of subjects: 472
Study 36820984 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 420
Study 36820984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 36820983 — intervention group
Group type: EXPERIMENTAL
Intervention: IV golimumab
Number of subjects: 1270
Study 36820983 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 1270
Study 36820983 — intervention group
Group type: EXPERIMENTAL
Intervention: IV golimumab and Infliximab
Number of subjects: 1270
Study 36821132 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy plus lapatinib
Number of subjects: 630
Study 36821132 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemoradiotherapy plus placebo
Number of subjects: 630
Study 36821333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 3
Study 36821333 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 3
Study 36821333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 3
Study 36821334 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session version of the eating disorder prevention program
Number of subjects: 63
Study 36821334 — intervention group
Group type: COMPARATOR
Intervention: Two-session version of the eating disorder prevention program
Number of subjects: 63
Study 36821344 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD Coach app
Number of subjects: 0
Study 36821354 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks
Number of subjects: 18
Study 36821354 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 18
Study 36821366 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 264
Study 36821366 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS and phone calls
Number of subjects: 264
Study 36821366 — intervention group
Group type: COMPARATOR
Intervention: Routine standard care
Number of subjects: 264
Study 36821406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 64
Study 36821575 — intervention group
Group type: EXPERIMENTAL
Intervention: Keystone flap for wide excision defects
Number of subjects: 0
Study 36821575 — intervention group
Group type: EXPERIMENTAL
Intervention: Digit-sparing alternative for subungual melanoma
Number of subjects: 0
Study 36821575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy with predictive nomograms
Number of subjects: 0
Study 36821575 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy with immediate lymphatic reconstruction
Number of subjects: 0
Study 36821575 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive modalities for in-transit melanoma management
Number of subjects: 0
Study 36821613 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombospondin Type-1 Domain 7A Autoantibodies
Number of subjects: 0
Study 36821617 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36821768 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel) autologous anti-CD19 CAR T-cell therapy (2 × 10^6 cells per kg)
Number of subjects: 101
Study 36821768 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel) autologous anti-CD19 CAR T-cell therapy
Number of subjects: 101
Study 36821775 — intervention group
Group type: EXPERIMENTAL
Intervention: REL-1017
Number of subjects: 0
Study 36821775 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 36821787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Overload (FO) ≥ 5% at Day 1
Number of subjects: 5079
Study 36821787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Overload (FO) ≥ 10% at Day 1
Number of subjects: 5079
Study 36821787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Overload (FO) peak at Day 2
Number of subjects: 5079
Study 36821787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Overload (FO) ≥ 5% at Day 2
Number of subjects: 5079
Study 36821787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Overload (FO) ≥ 10% at Day 2
Number of subjects: 5079
Study 36821818 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring with ePROs and biometrics (blood pressure, oxygen saturation, pulse, weight, temperature)
Number of subjects: 36
Study 36821833 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital integrated health care platform (group B)
Number of subjects: 294
Study 36821833 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital integrated health care platform with feedback (group C)
Number of subjects: 294
Study 36821833 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetes care (group A)
Number of subjects: 294
Study 36821841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 9723
Study 36821841 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 9723
Study 36821847 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 195
Study 36821847 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 195
Study 36821851 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Number of subjects: 241
Study 36821851 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 241
Study 36822031 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone delivered problem-solving treatment
Number of subjects: 99
Study 36822031 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 99
Study 36822079 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecan-enriched diet (68 g of pecans/d)
Number of subjects: 44
Study 36822079 — intervention group
Group type: COMPARATOR
Intervention: Control (nut-free diet)
Number of subjects: 44
Study 36822130 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib
Number of subjects: 92
Study 36822161 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus camrelizumab therapy
Number of subjects: 34
Study 36822161 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy
Number of subjects: 34
Study 36822187 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 55
Study 36822187 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Aerobic Training (MAT)
Number of subjects: 55
Study 36822238 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application for anthropometric body measurements
Number of subjects: 322
Study 36822255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Shenfu injection (80mL Shenfu injection + 70mL 5% glucose injection)
Number of subjects: 326
Study 36822255 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (150mL 5% glucose injection)
Number of subjects: 326
Study 36822256 — intervention group
Group type: EXPERIMENTAL
Intervention: Bard Covera Plus covered stent mated with multibranched endovascular repair or iliac branch devices
Number of subjects: 284
Study 36822256 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive relining stents
Number of subjects: 284
Study 36822256 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific devices
Number of subjects: 284
Study 36822279 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of single fibroids
Number of subjects: 2578
Study 36822279 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of multiple fibroids
Number of subjects: 2578
Study 36822279 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of small fibroid volume
Number of subjects: 2578
Study 36822279 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of fibroids (any type)
Number of subjects: 2578
Study 36822279 — intervention group
Group type: COMPARATOR
Intervention: Pregnancies without fibroids
Number of subjects: 2578
Study 36822371 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating capsule, once daily, 5 days a week for 8 weeks
Number of subjects: 312
Study 36822371 — intervention group
Group type: COMPARATOR
Intervention: Placebo, once daily, 5 days a week for 8 weeks
Number of subjects: 312
Study 36822394 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein, mycoprotein-rich, non-animal-derived diet
Number of subjects: 16
Study 36822394 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet
Number of subjects: 16
Study 36822634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecleralimab (4 mg once-daily inhaled)
Number of subjects: 28
Study 36822634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 36822667 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (durva) with radiation therapy (RT) for 7 weeks followed by adjuvant durvalumab for 1 year
Number of subjects: 26
Study 36822667 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (durva) with radiation therapy (RT) for 7 weeks
Number of subjects: 26
Study 36822669 — intervention group
Group type: EXPERIMENTAL
Intervention: I/T/DIN/GM-CSF
Number of subjects: 17
Study 36822669 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 17
Study 36822669 — intervention group
Group type: COMPARATOR
Intervention: I/T/TEMS
Number of subjects: 17
Study 36822801 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Mother Healthy Baby psychosocial intervention delivered by non-specialist providers
Number of subjects: 35
Study 36822808 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in homeless population during first testing session
Number of subjects: 1249
Study 36822808 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in homeless population during second testing session
Number of subjects: 1249
Study 36822808 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 seroprevalence in general population during first testing session
Number of subjects: 1249
Study 36822808 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 seroprevalence in general population during second testing session
Number of subjects: 1249
Study 36822808 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased risk factors for COVID-19 infection
Number of subjects: 1249
Study 36822808 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased risk factors for COVID-19 infection
Number of subjects: 1249
Study 36822818 — intervention group
Group type: COMPARATOR
Intervention: Cardiac MR (CMR) assessment at 6 months and 12 months post-infection
Number of subjects: 534
Study 36822818 — intervention group
Group type: COMPARATOR
Intervention: Cardiac MR (CMR) assessment
Number of subjects: 534
Study 36822818 — intervention group
Group type: COMPARATOR
Intervention: Comparison with 92 healthy controls
Number of subjects: 534
Study 36822817 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare worker status
Number of subjects: 168
Study 36822839 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3640254 (GSK'254) 200 mg once daily from Days 11 to 20 and a single dose of cocktail + GSK'254 200 mg on Day 21
Number of subjects: 20
Study 36822839 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3640254 (GSK'254) 200 mg once daily
Number of subjects: 20
Study 36822922 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation (LT)
Number of subjects: 0
Study 36822922 — intervention group
Group type: COMPARATOR
Intervention: Triplet chemotherapy + antiEGFR (Control)
Number of subjects: 0
Study 36823106 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4017
Number of subjects: 32
Study 36823106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 36823150 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day orally; neoadjuvant phase for 42 days and adjuvant phase to 12 months)
Number of subjects: 0
Study 36823150 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC group; gemcitabine 1250 mg/m2, dosage not fully specified)
Number of subjects: 0
Study 36823164 — intervention group
Group type: EXPERIMENTAL
Intervention: Home non-invasive mechanical ventilation (HMV) with home oxygen therapy (HOT)
Number of subjects: 0
Study 36823164 — intervention group
Group type: COMPARATOR
Intervention: Home oxygen therapy (HOT) alone
Number of subjects: 0
Study 36823200 — intervention group
Group type: EXPERIMENTAL
Intervention: gB/MF59 vaccine candidate
Number of subjects: 0
Study 36823302 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorasidenib 50 mg once daily (q.d.)
Number of subjects: 49
Study 36823302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg once daily (q.d.)
Number of subjects: 49
Study 36823302 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 49
Study 36823349 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg every 3 weeks for four cycles, then 1000 mg every 6 weeks
Number of subjects: 377
Study 36823396 — intervention group
Group type: EXPERIMENTAL
Intervention: 2022 ELN favorable group
Number of subjects: 1637
Study 36823396 — intervention group
Group type: EXPERIMENTAL
Intervention: 2022 ELN adverse group
Number of subjects: 1637
Study 36823396 — intervention group
Group type: EXPERIMENTAL
Intervention: 2022 genetic-risk groups
Number of subjects: 1637
Study 36823396 — intervention group
Group type: COMPARATOR
Intervention: Intermediate and adverse groups in patients aged ≥60 years
Number of subjects: 1637
Study 36823396 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-risk and adverse-risk patients in younger African-American patients
Number of subjects: 1637
Study 36823396 — intervention group
Group type: COMPARATOR
Intervention: Favorable and intermediate groups in younger African-American patients
Number of subjects: 1637
Study 36823396 — intervention group
Group type: COMPARATOR
Intervention: Favorable and intermediate groups in Hispanic patients
Number of subjects: 1637
Study 36823396 — intervention group
Group type: EXPERIMENTAL
Intervention: 2022 and 2017 ELN classifications
Number of subjects: 1637
Study 36823396 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable-risk patients with myelodysplasia-related mutations
Number of subjects: 1637
Study 36823526 — intervention group
Group type: EXPERIMENTAL
Intervention: PriCARE/CARIÑO intervention with usual care
Number of subjects: 0
Study 36823526 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study 36823559 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogue-based webinar intervention facilitated by a LTCW and a medical expert, guided by an evidence-based COVID-19 vaccine decision tool.
Number of subjects: 0
Study 36823559 — intervention group
Group type: EXPERIMENTAL
Intervention: Curated social media web application intervention featuring interactive, dynamic content about COVID-19 and relevant vaccines.
Number of subjects: 0
Study 36823559 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual practice directing participants to online public health information about COVID-19 vaccines.
Number of subjects: 0
Study 36823559 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (webinar, social media app, enhanced usual practice)
Number of subjects: 0
Study 36823567 — intervention group
Group type: EXPERIMENTAL
Intervention: PE plus MCE
Number of subjects: 120
Study 36823567 — intervention group
Group type: EXPERIMENTAL
Intervention: MCE
Number of subjects: 120
Study 36823567 — intervention group
Group type: COMPARATOR
Intervention: PE alone
Number of subjects: 120
Study 36823645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 0
Study 36823645 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 0
Study 36823645 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 0
Study 36823645 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth delivery of treatments
Number of subjects: 0
Study 36823645 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing communication techniques
Number of subjects: 0